Virginia Catalyst and the Commonwealth Health Research Board Awards $300,000 Grant to Study Severe Liver Disease
Virginia Biosciences Health Research Corporation, now known as Virginia Catalyst, and the Commonwealth Health Research Board (CHRB) have partnered to award a $300,000 grant to a team from Sanyal Biotechnology, Eastern Virginia Medical School and George Mason University.
The grant aims to help accelerate the commercialization of Sanyal Biotechnology’s innovative DIAMONDTM mouse model, which is being commercialized for preclinical assessment of therapeutic agents for non-alcoholic steatohepatitis (NASH), a severe liver disease that can lead to fibrosis, cirrhosis and liver cancer.
Virginia Catalyst will provide $100,000 in funding while CHRB will provide $200,000. Sanyal Biotechnology is investing $166,000 as matching funds for the project titled, “Characterization of GUT Microbiome and Liver Cell Populations to Accelerate Commercialization of the DIAMONDTM Mouse Model.”